pharmaphorum

JULY 23, 2021

Could virtual reality tools be effective in helping patients ‘unlearn’ their chronic pain? p harmaphorum speaks to Professor Christopher Eccleston from the University of Bath’s Centre of Pain Research to find out how digital therapeutics are shaping the future of pain management. A digital software developed by Finnish drugmaker Orion is aiming to address chronic pain conditions using virtual reality (VR) devices that provide an immersive gamified therapeutic treatment program.

145

145

Outsourcing Pharma

JULY 19, 2021

A recent study indicates patients taking the cholesterol-lowering drugs prior to COVID hospitalization are far less likely to die as a result of the virus.

Hospitals 111

Hospitals 111

Pharma Mirror

JULY 23, 2021

Immunotherapy and Tyrosine Kinase Inhibitor Combination Approved for the Treatment of Patients With Advanced Endometrial Carcinoma Study Results Demonstrated Statistically Significant Improvements in Overall Survival, Progression-Free Survival and Overall Response Rate, Helping to Address a Significant Unmet Need in Advanced Endometrial Carcinoma TOKYO and KENILWORTH, N.J. – (JCN Newswire) – Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A.

FDA 52

FDA 52

Birth Control Pharmacist

JULY 21, 2021

Educational programming for pharmacy students and practicing pharmacists on medication abortion is limited. Twenty years ago, the FDA approved mifepristone. Since then, medication has transformed the accessibility of abortion. In 2017, about 39% of abortions in the United States were medication abortions, reflecting many people’s preference for this option. 1 As reproductive health services are transforming, it is important that pharmacy services become adaptive to them.

FDA 52

FDA 52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

JULY 22, 2021

Pfizer has pledged a whopping $1 billion upfront for rights to an Arvinas drug for breast cancer from its protein degrader platform, which harnesses cells’ natural protein-denaturing machinery to remove rogue proteins associated with disease. The deal focuses on ARV-471, currently in phase 2 testing for advanced breast cancer patients whose tumours expresses oestrogen receptors – so are hormone sensitive – but test negative for HER2 receptors that would make them candidates for treatment w

116

116

Outsourcing Pharma

JULY 20, 2021

A recent survey conducted by dosing technology firm found that the vast majority (85%) of patients think that personalized medicine stands to improve care.

105

105

Pharma Marketing Network

JULY 21, 2021

At the PMN Summer Summit of 2021, leaders from an array of disciplines and roles within the industry came together to discuss the all-important concept of Customer Experience, and specifically, how CX continues to evolve in the aftermath of the global pandemic crisis, COVID-19. The summit consisted of three panel discussions: “Coordinated CX: Moving Beyond Campaign Management,” “Digital Customer Experience and Analytics,” and “The Engagement Matrix: A Holistic View of CX.

Communication 52

Communication 52

pharmaphorum

JULY 23, 2021

GlaxoSmithKline has said that Brian McNamara – currently head of its three-year-old consumer health joint venture with Pfizer – will retain the top job at the business after it is hived off into a separate company next year. The appointment, which had been expected, was confirmed in a statement by GSK’s board today. McNamara has been with GSK since 2015, when he joined the company as head of consumer health for Europe and the Americas, and previously worked for 10 years at Novartis, ultima

Vaccines 111

Vaccines 111

Outsourcing Pharma

JULY 20, 2021

The pharma firm's partnership with 26 US Black colleges includes a $13.7m investment in trial and research centers at Morehouse School of Medicine.

98

98

indispensable health

JULY 20, 2021

Confused Drug Names, Formerly Known as Look-Alike Sound-Alike (LASA) Medications For many years, the Institute for Safe Medication Practices (ISMP), has acknowledged that similar medication names, brand or generic, pose a real risk of medication errors in any healthcare setting. Recently, the nomenclature of Look-Alike Sound-Alike (LASA) medications were changed to Confused Drug Names.

Labelling 52

Labelling FDA 52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharma Marketing Network

JULY 21, 2021

At the PMN Summer Summit of 2021, leaders from an array of disciplines and roles within the industry came together to discuss the all-important concept of Customer Experience, and specifically, how CX continues to evolve in the aftermath of the global pandemic crisis, COVID-19. The summit consisted of three panel discussions: “Coordinated CX: Moving Beyond Campaign Management,” “Digital Customer Experience and Analytics,” and “The Engagement Matrix: A Holistic View of CX.

Communication 52

Communication 52

pharmaphorum

JULY 22, 2021

In just over a year, Celltrion Healthcare says it has identified and delivered a potential treatment for COVID-19. pharmaphorum spoke to Kwon Ki-sung, Head of Celltrion’s R&D unit, to learn more. Celltrion’s COVID-19 therapeutic, CT-P59, is a monoclonal antibody (mAb) with activity against COVID-19. It was identified as a potential treatment through the screening of antibody candidates from recovered patients and selecting those that showed the highest potency in neutralising the SARS-CoV-2

Communication 105

Communication Packaging Pharmaceutical Companies Pharmaceutical Companies 105

Outsourcing Pharma

JULY 19, 2021

The World Health Organization hopes to encourage the development of novel therapies for tuberculosis by spotlighting key clinical study characteristics.

64

64

The Spirit Pharmacist

JULY 19, 2021

Putting Spirit Back in Psychiatry. The word root 'psyche' can be translated to the human mind, soul, or spirit. Therefore, psychiatry is literally a field of medicine that is inherently about healing the spirit. Yet, in our current day and age the biological paradigm of mental health has led most to forget this. Instead of talking about what a person needs to feel happy, fulfilled, aligned, connected, valued, and like the most authentic version of themselves in psychiatry, the focus is on 'neuro

FDA 52

FDA 52

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Med Ed 101

JULY 21, 2021

Phosphodiesterase-5 inhibitors, or PDE-5 inhibitors, are often the first-line therapy for erectile dysfunction. PDE-5 inhibitors do not produce an erection in the absence of stimulation – rather they enhance the effect of nitric oxide by inhibiting PDE-5-mediated hydrolysis of cGMP, which is present during stimulation. Below we provide a comparison of PDE-5 Inhibitors.

40

40

pharmaphorum

JULY 21, 2021

Think of the R&D dollars that could be saved if artificial intelligence (AI) modelling could tell you at an early stage whether a drug was likely to succeed in clinical trials, and ultimately reach the market. In 2019, a team at Massachusetts Institute of Technology (MIT) in the US came up with just such a model, and found that it was able to perform “better than random” at predicting the outcome of a clinical trial or development programme.

Data Entry 105

Data Entry Compounding 105

Outsourcing Pharma

JULY 22, 2021

The health data specialist and pharma firm are partnering on solutions around remote collection of digital data for detection and monitoring of treatments.

52

52

Pharma Times

JULY 22, 2021

Verquvo cleared for the treatment of symptomatic chronic heart failure in patients with reduced ejection fraction

53

53

Med Ed 101

JULY 18, 2021

Last week, the FDA approved finerenone (Kerendia) to treat patients with chronic kidney disease (CKD) associated with type 2 diabetes. Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA). The approval of finerenone was due to the results of the recently completed FIDELIO-DKD trial, which demonstrated the protective effects of finerenone.

FDA 40

FDA 40

pharmaphorum

JULY 20, 2021

EPG Health’s Allen Wellings assesses future symposia and congress models, outlining some learnings about content and reach. COVID-19 had a huge, and very obvious, initial impact on medical congresses and symposia when 2020’s lockdowns took effect, with many events struggling to move quickly enough to a purely digital format. While many did succeed in creating digital learning environments during those difficult early months of the pandemic, there are some clear learnings for pharma companies in

Pharmaceutical Companies 105

Pharmaceutical Companies Pharmaceutical Companies 105

Outsourcing Pharma

JULY 19, 2021

The process management solutions firm says drug companies could use contract data to get a better handle on predicting demand and adjusting product output.

52

52

Pharma Times

JULY 23, 2021

Real-world data shows jab is effective after one dose against hospitalisation/death caused by Beta and Delta variants

Vaccines 51

Vaccines 51

The deprescribing.org Blog

JULY 21, 2021

Hello, deprescribers. Today we have Dr. Katharina Jungo (University of Bern, Switzerland) summarizing key findings from her recent PhD dissertation that explored ways to optimize medication use in older people with multimorbidity and polypharmacy. Take it away, Katharina! Older adults with multiple chronic conditions, who regularly use different medications, are at high risk of using potentially inappropriate medications.

Communication 52

Communication 52

pharmaphorum

JULY 19, 2021

America’s biopharmaceutical industry says it is “ready to do its part” in building a stronger, more resilient, affordable, and equitable health care system for all. COVID-19 highlighted both the challenges of the US healthcare system and the huge change potential of the country’s pharmaceutical industry. Now, as vaccination continues at pace, the sector has pledged to help “build back better”, by lowering barriers between medical innovations and the patients who need them.

Insurance 105

Insurance Vaccines Documentation Immunization 105

Outsourcing Pharma

JULY 22, 2021

This monthâs roundup of new excipients, manufacturing sites, partnerships, and other items includes news from DFE Pharma, Vetter, and other notable firms.

52

52

Pharma Times

JULY 20, 2021

A therapeutic dose of regdanvimab also reduced the viral load of the SARS-CoV-2 virus and inflammation in the lungs

51

51

Pharma Mirror

JULY 23, 2021

SOMERSET, N.J. — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it will commence the first phase of a planned $100 million expansion program at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities, supporting the growing European market demand for biologics manufacture and supply.

52

52

pharmaphorum

JULY 22, 2021

Bluebird bio has its first approval for Skysona (formerly Lenti-D), its gene therapy for children with the rare disease cerebral adrenoleukodystrophy (CALD), after getting the nod from the EU regulatory authority. The EMA has cleared Skysona (elivaldogene autotemcel) for use in CALD patients aged under 18 who have an ABCD1 genetic mutation and no matched sibling donor who could provide a stem cell transplant.

98

98

Outsourcing Pharma

JULY 21, 2021

A leader from the artificial intelligence solutions firm discusses how advanced analytical tools can help researchers make the most of mountains of data.

52

52

Pharma Times

JULY 22, 2021

PFIC is a rare and progressive liver disease affecting young children which can lead to cirrhosis and liver failure

50

50

pharmaphorum

JULY 20, 2021

The FDA has taken a longer than usual look at Ardelyx’ regulatory submission for tenapanor, a drug for high blood phosphate levels associated with chronic kidney disease (CKD), and found it wanting – sending the biotech’s shares into a tailspin. The US regulator had extended its review of the drug by three months – setting back its action date from April to 29 July – but now says that deficiencies in the marketing application “preclude discussion” of labelling and post-ma

FDA 98

FDA Labelling Communication 98

pharmaphorum

JULY 20, 2021

The EMA has kicked off a rolling review of a COVID-19 vaccine from Sanofi and GlaxoSmithKline, which started a 35,000-patient phase 3 trial in May. The vaccine – now dubbed Vidprevtyn – is based on a recombinant protein antigen developed by Sanofi’s vaccines unit Sanofi Pasteur, and also includes an immune-boosting adjuvant developed by GSK that aims to boost its efficacy.

Vaccines 98

Vaccines Immunization 98

pharmaphorum

JULY 20, 2021

Bayer subsidiary BlueRock Therapeutics has been granted a fast-track review by the FDA for DA01, its stem cell-based therapy for Parkinson’s disease which is currently in early-stage clinical testing. The FDA designation allows for benefits such as more frequent meetings and communication with the regulator during clinical development, and a truncated six-month review time.

FDA 98

FDA Communication Immunization 98

pharmaphorum

JULY 19, 2021

Shares in Cytokinetics surged after it reported positive mid-stage results for CK-274, a drug for hypertrophic cardiomyopathy (HCM) that could tread on the toes of Bristol-Myers Squibb’s mavacamten – acquired as part of its $13.1 billion takeover of MyoKardia last October. In HCM, the heart muscle become thickened and in some patients can obstruct blood flow, causing symptoms like chest pain and palpitations.

Labelling 98

Labelling FDA 98